To address current gaps in expert guidance related to the recent development and commercial availability of new non-statin agents, the American College of Cardiology today published an expert consensus decision pathway on the role of non-statin therapies. statins to lower LDL-C in the treatment of atherosclerotic cardiovascular disease. disease risk reduction (ASCVD).
The document provides guidance on clinical scenarios not covered in the 2018 AHA/ACC Guidelines on Blood Cholesterol Monitoring and refines criteria for treatment of individuals determined by reference levels of LDL-C. The clinical policy focuses on individuals at very high and not very high risk for future ASCVD events, individuals currently with or without a clinical diagnosis of familial hypercholesterolemia, primary prevention for individuals with and without diabetes, and individuals on statins. associated side effects. The writing committee also addresses factors to consider in the physician-patient discussion, reinforcing patient preference regarding the addition of nonstatin therapies.
the 2022 ACC Expert Consensus Decision Pathway on the role of non-statin therapies to lower LDL cholesterol in managing the risk of atherosclerotic cardiovascular diseases will post online at Journal of the American College of Cardiology on Thursday, August 25, 2022 at 2:00 p.m. ET. It was endorsed by the National Lipid Association.
American College of Cardiology